Selumetinib

Introduction Overview

Generic Name

selumetinib

Brand Name

Koselugo

Dosage Form

oral capsule (10 mg, 25 mg)

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption:
Selumetinib is administered orally in capsule form and exhibits moderate to good oral bioavailability. The drug is absorbed through the gastrointestinal tract, with peak plasma concentrations (Cmax) typically attained within 1.5 to 2.5 hours post-dose. Food does not significantly alter the systemic exposure; hence, the medication can be taken with or without food. The absorption process is not significantly affected by the presence of gastric pH-modifying agents. Variable absorption kinetics have been noted in pediatric patients due to differences in metabolic rate and gastrointestinal transit. Clinical trials indicate consistent absorption in children aged 2 years and older, with dose adjustments made based on body surface area.

Distribution:
Selumetinib demonstrates a moderate volume of distribution, indicating distribution beyond the plasma into tissues. Approximately 98% of selumetinib binds to plasma proteins, predominantly albumin and alpha1-acid glycoprotein. The drug crosses cellular membranes to reach intracellular targets, specifically MEK1 and MEK2 kinases. Preclinical studies indicate its ability to penetrate tumor tissue effectively, facilitating inhibition of aberrant RAF-MEK-ERK pathway activity within neurofibroma cells. Limited data suggest minimal penetration across the blood-brain barrier, although this is not the primary therapeutic target. Factors such as body composition and plasma protein levels may influence distribution in pediatric populations.

Metabolism:
Selumetinib undergoes hepatic metabolism primarily via cytochrome P450 enzymes, mainly CYP1A2 and CYP2C19 isoforms. The drug is converted into active and inactive metabolites, with the major metabolic pathway involving oxidative biotransformation. Phase II conjugation through glucuronidation also contributes to its clearance. Studies indicate that metabolism can be influenced by liver functional status; moderate hepatic impairment (Child-Pugh B) requires dosage adjustment to reduce exposure, whereas severe impairment lacks established dosing guidelines due to limited data. Inhibition or induction of CYP enzymes by concomitant medications may alter selumetinib plasma levels, necessitating careful monitoring.

Elimination:
The elimination of selumetinib occurs predominantly via hepatic routes, with metabolites excreted in both feces and urine. The reported elimination half-life ranges from 5 to 8 hours, supporting twice-daily dosing. Renal excretion of unchanged drug is minimal. Steady-state concentrations are generally reached within 7 days of consistent dosing. Clearance rates may be decreased in patients with hepatic dysfunction, requiring dose modifications. There is no evidence of accumulation with repeated dosing in patients with normal hepatic and renal function. Clinical monitoring is advised to identify potential alterations in elimination that could impact toxicity or efficacy.

Dosage Forms

Available Dosage Forms:
Koselugo is available as an oral capsule formulated in two strengths to facilitate precise dosing based on patient-specific factors such as body surface area:
- Capsule 10 mg
- Capsule 25 mg

Dosages for Adults and Adolescents:
Koselugo is primarily indicated and dosed for pediatric patients aged 2 years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. The recommended dosage is 25 mg/m2 administered orally twice daily approximately every 12 hours. This dosing regimen is continued until disease progression or unacceptable toxicity occurs. Dosing based on body surface area allows for tailored drug exposure given the pediatric population's ongoing growth and metabolic variability.

Specific Patient Populations:
- Pediatric Patients: Approved for children aged 2 years and above; safety and efficacy in those under 2 years have not been established. Dose adjustments are based on growth, body surface area changes, and tolerability.
- Hepatic Impairment: For moderate hepatic impairment (Child-Pugh B), the recommended dose is reduced to 20 mg/m2 orally twice daily. No established dosing exists for severe impairment (Child-Pugh C).
- Renal Impairment: No specific dosing recommendations; elimination is minimally impacted by renal function, but monitoring is suggested.

Clinical guidelines emphasize strict adherence to prescribed dosing, ensuring capsules are swallowed whole with water and not crushed or chewed due to possible alteration in drug release and absorption. The dosing interval of approximately every 12 hours should be maintained to optimize drug plasma levels and therapeutic efficacy.

Mechanism Of Action

Koselugo (selumetinib) exerts its therapeutic effect primarily through selective inhibition of MEK1 and MEK2, which are dual-specificity mitogen-activated protein kinase kinases integral to the RAF-MEK-ERK signaling cascade. This pathway is crucial for regulating cellular proliferation, differentiation, and survival. In neurofibromatosis type 1 (NF1), a genetic mutation results in hyperactivation of this pathway, driving uncontrolled cell growth and formation of benign plexiform neurofibromas. By inhibiting MEK1/2, selumetinib disrupts phosphorylation and activation of ERK1/2, thereby attenuating downstream signaling involved in tumor growth.

At the molecular level, selumetinib competes with ATP for binding at the allosteric site of MEK1/2, inducing a conformational change that locks these kinases in an inactive state. This specific blockade prevents propagation of growth signals through the MAP kinase pathway. Unlike upstream inhibitors targeting RAF or RAS, selumetinib’s specificity for MEK minimizes off-target effects while effectively dampening aberrant proliferative signals.

Cellular studies demonstrate that treatment with selumetinib leads to reduced phosphorylation of ERK and its nuclear translocation, resulting in decreased transcription of genes essential for cell cycle progression and survival. This mechanism promotes apoptosis and inhibits proliferation within neurofibroma cells, contributing to tumor shrinkage observed clinically. Additionally, selumetinib’s modulation of the tumor microenvironment may impede neovascularization, further suppressing tumor expansion.

Clinically, inhibited MEK activity by selumetinib translates into significant reductions in plexiform neurofibroma volume and symptomatology in pediatric NF1 patients, as evidenced by pivotal clinical trials leading to FDA approval. Compared to other multikinase inhibitors, Koselugo offers a targeted approach with a mechanism tailored to the unique pathophysiology of NF1-related tumors, distinguishing it from broader kinase inhibitors with less specificity and higher toxicity profiles.

Pharmacological Actions

Selective inhibition of MEK1 and MEK2 kinases, disrupting the RAF-MEK-ERK signaling pathway.
Reduction of phosphorylation of ERK1/2, curtailing cellular proliferation and promoting apoptosis.
Modulation of signal transduction pathways implicated in oncogenic cell growth in neurofibromatosis type 1.
Induction of tumor shrinkage by blocking propagation of growth-factor signals.
Interference with tumor microenvironment dynamics possibly reducing angiogenesis.
Targeted multikinase inhibition offering therapeutic benefits with limited off-target effects.
Dose-dependent inhibition correlating with suppression of neurofibroma progression.
Pharmacodynamic activity demonstrated by decreased biomarker expression of MAP kinase pathway activity.
Synergistic potential when combined with other anti-neoplastic agents under investigation.
Safety profile allowing chronic administration in pediatric patients with ongoing monitoring.
Oral bioavailability facilitating outpatient treatment regimens.
Demonstration of reversible biochemical effects allowing dose adjustment in response to toxicity.
Minimal interference with cytochrome P450 enzymes aside from metabolism via CYP1A2 and CYP2C19.

Therapeutic Or Clinical Uses

Treatment of neurofibromatosis type 1 (NF1) in children aged 2 years and older with symptomatic, inoperable plexiform neurofibromas.
Management of benign tumors associated with NF1 by inhibiting tumor growth and reducing tumor volume.
Alternative therapy option where surgical resection of neurofibromas is not feasible.
Reduction of tumor-related morbidity and improvement in quality of life for NF1 pediatric patients.
Potential off-label investigation in other malignancies with aberrant MEK pathway activation.
Use in clinical trials exploring combination therapy with other targeted agents for NF1 and related tumors.
Palliative treatment to control tumor progression and related symptoms in pediatric oncology settings.
Management of Ras-MAPK pathway-driven tumors beyond NF1, pending further research.
Prevention of tumor progression in genetically predisposed pediatric cohorts.
Reduction of tumor-associated pain and functional impairment through targeted therapy.
Use in specialized pediatric oncology protocols considering growth and developmental factors.
Treatment continuation until disease progression or intolerable adverse effects arise.
Potential to delay or reduce the need for invasive surgical procedures in NF1 patients.

Side Or Adverse Effects

Vomiting
Stomach-area pain (abdominal discomfort)
Nausea
Dry skin
Muscle and bone pain
Fatigue or feeling of tiredness/lack of energy
Fever
Mouth sores (aphthous ulcers)
Headache
Redness and irritation around the fingernails
Itching (pruritus)
Diarrhea, which may be severe and requires prompt medical attention
Skin rash that may be widespread and severe with possible blistering or peeling
Ocular adverse events including blurred vision, floaters, loss of vision, and other visual disturbances potentially leading to blindness
Cardiac effects such as reduced left ventricular ejection fraction leading to symptoms including shortness of breath, swelling of ankles, persistent coughing, and increased heart rate
Muscle-related toxicity including rhabdomyolysis evidenced by muscle pain, spasms, weakness, and dark urine
Laboratory abnormalities such as elevated creatine phosphokinase (CPK) levels signaling muscle damage
Potential hepatotoxicity, especially in patients with pre-existing liver impairment
Increased risk of bleeding due to presence of vitamin E in formulation and interaction with anticoagulants
Potential for serious diarrhea requiring dose modifications or discontinuation
Injection site reactions are not applicable since the medication is oral

Precautions

Baseline and periodic cardiac function monitoring due to risk of decreased cardiac output and heart failure.
Ophthalmologic evaluations before and during treatment to detect early signs of eye toxicity.
Cautious use in patients with hepatic impairment; dose reductions required for moderate impairment.
Avoidance of concomitant use with grapefruit juice, grapefruit products, and St. John's wort, which can affect drug metabolism.
Use effective contraception for females of reproductive potential and males with partners who can become pregnant during treatment and for one week after last dose.
Discontinue breastfeeding during treatment and for at least one week post last dose due to unknown drug excretion into breast milk.
Immediate reporting of severe diarrhea to healthcare provider for management to avoid dehydration or electrolyte imbalance.
Caution advised in patients with bleeding disorders or concomitant use of anticoagulants due to vitamin E content increasing bleeding risk.
Dose adjustments or interruption may be necessary upon occurrence of serious adverse reactions such as rash, muscle toxicity, or cardiac effects.
Ensure adequate hydration during therapy, especially in the presence of diarrhea or vomiting.
Educate patients on symptoms of vision changes, cardiac symptoms, and muscle pain requiring prompt medical evaluation.
Not recommended for children under 2 years old as safety and efficacy have not been established.
Dose adjustments may be warranted with changes in body surface area during growth in pediatric patients.
Avoid abrupt discontinuation without consulting a healthcare provider to prevent disease progression.
Regular monitoring of creatine phosphokinase (CPK) levels during treatment to assess muscle toxicity.

Warnings

Risk of heart problems including decreased left ventricular ejection fraction, which may manifest as persistent cough, wheezing, shortness of breath, ankle/foot swelling, fatigue, or increased heart rate requiring medical evaluation.
Potential for severe and vision-threatening eye problems; immediate reporting and regular vision assessments are imperative.
Severe diarrhea may lead to dehydration and electrolyte disturbances; prompt medical attention is necessary upon onset.
Serious skin rashes including widespread rash, peeling, or blistering that may necessitate dose reduction or discontinuation.
Risk of muscle toxicity (rhabdomyolysis) leading to muscle damage, pain, spasms, weakness, and dark urine; requires monitoring and intervention.
Potential teratogenicity and fetal harm; pregnancy testing and effective contraception are mandatory during treatment.
Unknown safety profile for use in children under 2 years of age; not recommended in this population.
Possible increased bleeding risk when used concomitantly with anticoagulants or antiplatelet agents due to vitamin E content.
Risk of hepatotoxicity especially in patients with pre-existing liver disease; monitoring liver function tests is advised.
Not intended for use in pregnant or breastfeeding women due to potential harm to fetus and infant.
Patients should avoid grapefruit products and St. John's wort as they may significantly affect drug plasma levels.
Abrupt discontinuation may result in rapid tumor progression; dose adjustments should be under medical supervision.
Consideration of interactions with other kinase inhibitors or antineoplastic agents that might potentiate adverse events.
Potential for drug accumulation and toxicity in cases of severe hepatic impairment where dosing guidelines are not established.
Risk of serious adverse events mandates multidisciplinary monitoring in specialized clinical settings.

Contraindication

Known hypersensitivity to selumetinib or any component of the Koselugo formulation.
Children younger than 2 years of age due to lack of safety and efficacy data.
Concurrent use with grapefruit products or strong CYP450 inducers/inhibitors without proper medical supervision.
Pregnancy unless the potential benefits outweigh the serious risks to the fetus; effective contraception must be employed.
Breastfeeding during treatment and for at least one week post last dose due to unknown breastfeeding safety.
Severe hepatic impairment (Child-Pugh C) due to undefined dosing and increased risk of toxicity.
Concurrent use with medications known to exacerbate cardiac dysfunction without close cardiac monitoring.
Patients with active uncontrolled infections or significant comorbidities precluding therapy with kinase inhibitors.
Known bleeding disorders or on anticoagulants without risks assessment due to increased bleeding risk.
Use in patients with pre-existing severe ocular disease should be carefully evaluated.
Concurrent therapy with other MEK inhibitors unless under approved combination protocols.
Patients who cannot swallow capsules whole or have severe gastrointestinal malabsorption issues preventing adequate absorption.

Drug Interactions

Avoid concomitant intake of grapefruit juice or grapefruit-containing products which inhibit CYP3A4 and can increase selumetinib plasma levels.
St. John's wort and other strong CYP450 inducers may reduce selumetinib effectiveness by increasing its metabolism.
Concomitant use with anticoagulants or antiplatelet agents may heighten bleeding risk due to vitamin E content in Koselugo.
Drugs that impair hepatic function may increase the risk of selumetinib toxicity due to altered metabolism.
No significant interactions reported with common pediatric vaccines, but clinical monitoring is advised.
Caution with other kinase inhibitors or targeted therapies that may have additive toxicities.
Potential interactions with CYP1A2 and CYP2C19 inhibitors or inducers affecting drug plasma concentrations.
No established interaction with common analgesics like acetaminophen; however, NSAIDs should be used cautiously due to bleeding risk.
Co-administration with strong CYP3A4 inhibitors has not been extensively evaluated; clinical monitoring recommended.
Vitamin supplements containing vitamin E should be disclosed to avoid synergistic bleeding risk.
Monitoring advised when used with medications that affect cardiac function due to additive cardiotoxicity potential.
Certain anti-epileptics may alter hepatic metabolism impacting selumetinib levels and efficacy.
Concomitant use with P-glycoprotein substrates or inhibitors requires clinical vigilance for altered drug levels.
Potential interaction with immunosuppressants used in transplant recipients requires monitoring.
Patients should inform healthcare providers about all herbal and over-the-counter supplements to assess interaction risk.

Preparations Of The Drug

Selumetinib is formulated as oral capsules in two strengths: 10 mg and 25 mg for precise dosing.
Capsule shell compositions differ by strength with 10 mg capsules containing hypromellose, carrageenan, potassium chloride, titanium dioxide, carnauba wax, and purified water.
Printing inks on capsules contain shellac and iron oxides providing identification markings.
Inactive ingredients include vitamin E and polyethylene glycol succinate which may contribute to the drug's stability and bioavailability.
25 mg capsules contain color additives such as FD&C blue 2 and ferric oxides in shell and ink for drug identification.
The capsules should be stored in their original bottle containing a desiccant packet to protect from moisture.
Storage conditions specify room temperature away from heat and moisture with the bottle tightly closed.
Packaging is designed to maintain potency and prevent degradation, critical for pediatric dosing accuracy.
The medication is supplied by AstraZeneca Pharmaceuticals LP with strict adherence to Good Manufacturing Practices.
No generic formulations are currently available; Koselugo is a branded prescription medication.
The drug is supplied with a Medication Guide to educate patients and caregivers on proper administration and safety.
Koselugo capsules are not to be crushed, chewed, or opened to prevent altered absorption or mucosal irritation.
The formulation allows for convenient twice-daily oral administration facilitating outpatient treatment compliance.
Each batch undergoes rigorous quality control testing for potency, dissolution, and sterility.